CVS Health is not a pharmacy chain anymore. It is a healthcare machine with four moving parts: Aetna sells health insurance to roughly 37 million people, CVS Caremark manages prescription drug benefits for about 87 million plan members, roughly 9,000 CVS Pharmacy stores fill prescriptions and sell health products, and a newer care delivery arm runs more than 1,000 walk-in and primary care clinics through MinuteClinic and Oak Street Health. Money comes in through insurance premiums, fixed monthly payments from the government for Medicare members, pharmacy benefit management fees, and prescription sales at the counter. Each business feeds the others: an Aetna member can fill prescriptions at CVS Pharmacy, get managed by CVS Caremark, and see a doctor at an Oak Street Health clinic. The diagram below traces where the money flows.
How CVS Health Makes Money
flowchart TD
A["Members & Patients
37M+ people"] --> B["Health Care Benefits
Insurance Plans"]
A --> C["Pharmacy & Retail
9,000 locations"]
A --> D["Health Services
Clinics & PBM"]
B -->|"Premiums &
Capitation
~20% fed revenue"| E["Revenue
265.1B"]
C -->|"Prescription Fills
1.9B annually"| E
D -->|"PBM Admin &
Care Services"| E
E -->|"16.6% gross
margin"| F["Operating
Cash Flow
10.6B"]
F --> G["Provider Networks
2M+ providers
63K pharmacies"]
G -->|"Better outcomes
lower costs"| B
G --> D
D -->|"Risk-based
value care"| H["Care Coordination
Signify + Oak Street"]
H -->|"Improved health
data feedback"| B
Five years of financial data tell a story of rapid growth followed by real strain. Revenue climbed from $214.8 billion in 2021 to $265.1 billion in 2025, a rise of more than $50 billion. But revenue growing does not mean the business is getting healthier. Free cash flow, the actual cash left over after the company pays its bills and keeps its operations running, fell from $15.7 billion in 2021 to $6.3 billion in 2024 before recovering slightly to $7.8 billion in 2025. That is a dramatic shrinkage. Net debt, meaning what the company owes minus what it holds in cash, moved in the wrong direction too, rising from $42.6 billion in 2021 to $54.1 billion in 2024 before easing to $52.0 billion in 2025. The company borrowed heavily to buy Signify Health for around $8 billion and Oak Street Health for around $10.6 billion, and those debts are still sitting on the balance sheet.
Free Cash Flow (2021 to 2025)
Free cash flow in billions of dollars. Revenue kept growing over the same period, but cash generation fell sharply before a partial recovery in 2025.
Gross margin tells the same story. The percentage of each dollar of revenue the company kept after direct costs was 18.1% in 2021. By 2023 it had fallen to 15.7%. It edged back to 16.7% in 2024 and held near that level at 16.6% in 2025. The insurance segment is the main reason for the pressure. Aetna collected premiums from members and from the government, then paid out more in medical costs than expected, especially in Medicare Advantage and individual exchange plans. In 2024 the Health Care Benefits segment posted an operating loss of $984 million. In 2025 it recovered to an adjusted operating income of $2.9 billion, but that recovery came after a brutal two-year stretch. Meanwhile the Oak Street Health acquisition triggered a $5.7 billion goodwill impairment charge in 2025, meaning the company wrote down the value of that business by $5.7 billion, an acknowledgment that it overpaid or that the business is performing below expectations.
$5.7B
Goodwill impairment charge on the Oak Street Health care delivery business recorded in 2025
What is a Medical Benefit Ratio?
The medical benefit ratio, or MBR, measures what share of insurance premium revenue gets paid out as medical costs. A ratio of 90% means 90 cents of every premium dollar goes to paying claims, leaving 10 cents for everything else. A higher ratio means less room to cover operating costs and make a profit. CVS tracks this number closely because even a small forecasting error can wipe out the thin margin on insurance products.
The Health Care Benefits segment spent 91.2% of its premium revenue on medical costs in 2025, down from 92.5% in 2024 but still far above the 86.2% it spent in 2023. That means for every dollar Aetna collected in premiums last year, just 8.8 cents was left before operating expenses. The core problem is timing. CVS sets insurance prices months before the policy year begins, based on predictions of what medical care will cost. If those predictions are wrong, the company absorbs the difference. In the first half of 2025 alone, CVS recorded over $900 million in extra reserves because actual health care costs came in worse than expected.
91.2%
Share of Aetna premium revenue spent on medical costs in 2025, leaving just 8.8 cents per dollar before operating expenses
The risks are specific, not generic. First, health care cost forecasting: every year CVS must guess what its members will spend on medical care, and if it guesses low it cannot go back and raise prices mid-year. Second, government payment rules: roughly 20% of CVS's total revenues in 2025 came from federal government contracts, primarily through Medicare. The government sets those payment rates annually, and it can cut them. Proposed 2027 Medicare Advantage rate increases are just 0.09% on average before risk score adjustments, according to a January 2026 advance notice from the government. Third, the pharmacy benefit management business faces pressure from clients demanding lower prices and a bigger share of the drug rebates CVS negotiates with manufacturers. Fourth, several states are considering laws that could bar pharmacies affiliated with a pharmacy benefit manager from operating, which would directly threaten the way CVS has structured its combined business.
2023
milestone
Oak Street Health acquisition completed
CVS completed its $10.6 billion purchase of Oak Street Health in May 2023, adding a network of primary care clinics serving Medicare patients. The deal was the centerpiece of CVS's plan to become a full healthcare provider. By 2025, the company recorded a $5.7 billion goodwill impairment on the Health Care Delivery unit, signalling that the business has not performed as expected. CVS also announced plans to close certain Oak Street Health clinics in 2026.
CVS also faces legal costs that are not going away. In 2025 the company recorded $1.2 billion in legacy litigation charges tied to two court decisions about past business practices, including $929 million in the Pharmacy and Consumer Wellness segment alone. An additional $320 million opioid litigation charge was recorded in the same year. These are not small numbers for a business where free cash flow is $7.8 billion.
$52.0B
Net debt at end of 2025, up from $42.6 billion in 2021, reflecting the cost of the Signify Health and Oak Street Health acquisitions
What is value-based care?
Traditional healthcare pays doctors and hospitals for each visit or procedure, which can encourage more treatment rather than better outcomes. Value-based care flips that model: providers get paid based on how healthy their patients stay, not how many services they deliver. CVS is betting that owning Oak Street Health clinics and Signify Health, which does health risk assessments, lets it manage costs better by keeping patients healthier before they need expensive treatment.
The integrated model is the whole thesis. CVS is trying to build a business where the same company that insures you also manages your prescriptions, sees you at a clinic, and checks on you at home. If that loop works, CVS can theoretically spot health problems early, reduce expensive hospital visits, and keep more of the premium dollar. The PBM business processed 1.9 billion prescriptions on a 30-day equivalent basis in 2025, and the retail pharmacy network covers roughly 63,000 pharmacy locations including CVS-owned stores. The scale is real. The question is whether the pieces actually produce the financial returns that justify holding them together.
CVS exited the public health insurance exchanges in all Aetna-operated states effective January 2026. That means the individual exchange business, which was a source of losses, is now gone. It shrinks the top line but also removes a known source of cost overruns.
The Bet
CVS can accurately predict what its millions of insurance members will spend on medical care year after year, and that accuracy improves as it gathers more data from its clinics, pharmacies, and benefit management operations. If it can, the integrated model generates a pricing advantage: better data means better forecasts, better forecasts mean premiums are set right, and premiums set right mean the insurance segment makes money instead of losing it. If the forecasting does not improve, or if government payment rates for Medicare keep tightening, the insurance business will keep consuming cash faster than the pharmacy and PBM businesses can generate it, and the debt load becomes harder to carry.
Open question
CVS spent roughly $18.6 billion acquiring Signify Health and Oak Street Health to build a care delivery arm, then wrote down $5.7 billion of that value in 2025 and announced clinic closures for 2026. The insurance business lost money in 2024 and barely recovered in 2025. Free cash flow has been cut by more than half since 2021 while debt has grown. Is CVS working through the expected pain of a difficult transformation that will eventually make the integrated model pay off, or has it discovered that owning clinics, insurance, and pharmacies together is harder and less profitable than the theory suggested?
Compiled · 10-K · FY2025
Health Care Cost Forecasting
The company sets insurance premiums months in advance based on predictions of what health care will cost. If actual medical costs turn out much higher than predicted, the company cannot raise prices mid-year to cover the difference, which can seriously hurt profits. Even small mistakes in these predictions can cause major financial problems.
Regulatory and Legislative Changes
The company depends heavily on government health programs like Medicare and Medicaid that are subject to frequent rule changes, rate cuts, and competitive bidding. New laws could restrict how the company's pharmacy benefit manager business operates, change drug pricing rules, or fundamentally restructure these programs, potentially cutting revenues significantly.
Insurance Reserve Estimates
The company must estimate how much money to set aside to pay insurance claims that haven't been submitted yet. During the first half of 2025, the company recorded over $900 million in reserves because actual health care costs were much worse than expected, primarily in individual exchange and Group Medicare Advantage plans. If these estimates are wrong, profits can be severely damaged.
PBM Business Competitive Pressure
The company's pharmacy benefit manager business faces intense price competition from rivals, with clients demanding lower prices, better service guarantees, and a larger share of drug manufacturer rebates. If the company cannot raise prices to keep up with rising drug costs, it will lose customers and profitability will decline.
Vertical Integration Regulatory Risk
The company owns both pharmacies and a pharmacy benefit manager business, which creates regulatory risk. Several states have proposed or passed laws that could prohibit pharmacies affiliated with a pharmacy benefit manager from being licensed, which could restrict how the company operates these combined businesses.
10-K Item 1A · Risk Factors
